Exclusion Criteria
Clinical evidence of ongoing grade 3 or 4 non-hematological toxicities from the initial standard dose cytarabine-based induction chemotherapy
boolean
Patients with a prior history of peripheral neuropathy of grade >= 2.
boolean
Clinical evidence of active CNS leukemic involvement.
boolean
Active and uncontrolled infection. Patients with an infection who are under active treatment with antibiotics and whose infections are controlled may be entered to the study.
boolean
Current evidence of invasive fungal infection (blood or tissue culture).
boolean
Current evidence of an active second malignancy except for non-melanoma skin cancer.
boolean
Uncontrolled medical problems, unrelated to the malignancy, or of sufficient severity that in the opinion of the investigator, impair a patient's ability to give informed consent or unacceptably reduce the safety of the proposed treatment.
boolean
Neurological or psychiatric disorders that would interfere with consent or study follow-up.
boolean
Known or suspected intolerance or hypersensitivity to the study drugs [or closely related compounds] or any of their stated ingredients. Study drugs being the antisense, cytarabine and idarubicin.
boolean
History of alcohol or other substance abuse within the last year.
boolean
Use of another investigational agent within the last 14 days prior to enrolment. Patients who have received a previous antisense agent in the last 90 days will be excluded.
boolean
Female patients who are pregnant, lactating, or with a positive pregnancy test at screening must be excluded.
boolean